← Back

Wire · regulatory

FDA rejects Capricor's Duchenne cell therapy deramiocel, citing data integrity violations in ...

Published

21 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at mlq.ai →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The FDA issued a complete response letter rejecting Capricor's cell therapy deramiocel for Duchenne muscular dystrophy due to serious data integrity violations in the Phase 3 HOPE-3 trial, including unauthorized statistical changes and blinding breaches that render the data unreliable.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You face tighter FDA scrutiny for clinical data integrity in rare disease cell therapies. Prepare to overhaul trial design and compliance to keep your Duchenne or similar therapies relevant.

◆ Coverage

4 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-denialcell-therapydata-integritydrug-approvalduchenne-muscular-dystrophy